Boston, MA & Hamilton, ON – March 23, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing…
Read More
Boston, MA & Hamilton, ON – March 4, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing…
Read More
Boston, MA & Hamilton, ON – February 6, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted…
Read More
Hamilton, ON & Boston, MA – January 13, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation…
Read More
Hamilton, ON & Boston, MA – January 10, 2020 – Fusion Pharmaceuticals Inc., a privately-held, clinical-stage precision oncology company developing…
Read More
Background Type I insulin-like growth factor receptor (IGF-1R) is a transmembrane protein which is overexpressed in solid tumors including non–small…
Read More
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, announced today that it will present a…
Read More
Lead investors Varian and OrbiMed, are joined by Perceptive Advisors, Pivotal bioVenture Partners, Rock Springs Capital and all existing investors…
Read More
BOSTON, MA and HAMILTON, ONTARIO, March 4, 2019 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer,…
Read More
BOSTON, Massachusetts and HAMILTON, Ontario—February 19, 2019- Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), today…
Read More
